Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 123

1.

Novel arylsulfonamide derivatives with 5-HT₆/5-HT₇ receptor antagonism targeting behavioral and psychological symptoms of dementia.

Kołaczkowski M, Marcinkowska M, Bucki A, Pawłowski M, Mitka K, Jaśkowska J, Kowalski P, Kazek G, Siwek A, Wasik A, Wesołowska A, Mierzejewski P, Bienkowski P.

J Med Chem. 2014 Jun 12;57(11):4543-57. doi: 10.1021/jm401895u. Epub 2014 May 23.

PMID:
24805037
2.

WS-50030 [7-{4-[3-(1H-inden-3-yl)propyl]piperazin-1-yl}-1,3-benzoxazol-2(3H)-one]: a novel dopamine D2 receptor partial agonist/serotonin reuptake inhibitor with preclinical antipsychotic-like and antidepressant-like activity.

Brennan JA, Graf R, Grauer SM, Navarra RL, Pulicicchio CM, Hughes ZA, Lin Q, Wantuch C, Rosenzweig-Lipson S, Pruthi F, Lai M, Smith D, Goutier W, van de Neut M, Robichaud AJ, Rotella D, Feenstra RW, Kruse C, Broqua P, Beyer CE, McCreary AC, Pausch MH, Marquis KL.

J Pharmacol Exp Ther. 2010 Jan;332(1):190-201. doi: 10.1124/jpet.109.157388. Epub 2009 Oct 14.

3.

Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents.

Campiani G, Butini S, Fattorusso C, Catalanotti B, Gemma S, Nacci V, Morelli E, Cagnotto A, Mereghetti I, Mennini T, Carli M, Minetti P, Di Cesare MA, Mastroianni D, Scafetta N, Galletti B, Stasi MA, Castorina M, Pacifici L, Vertechy M, Di Serio S, Ghirardi O, Tinti O, Carminati P.

J Med Chem. 2004 Jan 1;47(1):143-57.

PMID:
14695828
4.

Antidepressant and antipsychotic activity of new quinoline- and isoquinoline-sulfonamide analogs of aripiprazole targeting serotonin 5-HT₁A/5-HT₂A/5-HT₇ and dopamine D₂/D₃ receptors.

Zajdel P, Marciniec K, Maślankiewicz A, Grychowska K, Satała G, Duszyńska B, Lenda T, Siwek A, Nowak G, Partyka A, Wróbel D, Jastrzębska-Więsek M, Bojarski AJ, Wesołowska A, Pawłowski M.

Eur J Med Chem. 2013 Feb;60:42-50. doi: 10.1016/j.ejmech.2012.11.042. Epub 2012 Dec 5.

PMID:
23279866
5.

Conformationally constrained butyrophenones with mixed dopaminergic (D(2)) and serotoninergic (5-HT(2A), 5-HT(2C)) affinities: synthesis, pharmacology, 3D-QSAR, and molecular modeling of (aminoalkyl)benzo- and -thienocycloalkanones as putative atypical antipsychotics.

Raviña E, Negreira J, Cid J, Masaguer CF, Rosa E, Rivas ME, Fontenla JA, Loza MI, Tristán H, Cadavid MI, Sanz F, Lozoya E, Carotti A, Carrieri A.

J Med Chem. 1999 Jul 29;42(15):2774-97. Erratum in: J Med Chem 2000 Mar 23;43(6):1250.

PMID:
10425088
6.

ADN-1184 a monoaminergic ligand with 5-HT(6/7) receptor antagonist activity: pharmacological profile and potential therapeutic utility.

Kołaczkowski M, Mierzejewski P, Bieńkowski P, Wesołowska A, Newman-Tancredi A.

Br J Pharmacol. 2014 Feb;171(4):973-84. doi: 10.1111/bph.12509.

7.

Towards new 5-HT7 antagonists among arylsulfonamide derivatives of (aryloxy)ethyl-alkyl amines: Multiobjective based design, synthesis, and antidepressant and anxiolytic properties.

Canale V, Kurczab R, Partyka A, Satała G, Lenda T, Jastrzębska-Więsek M, Wesołowska A, Bojarski AJ, Zajdel P.

Eur J Med Chem. 2016 Jan 27;108:334-346. doi: 10.1016/j.ejmech.2015.11.040. Epub 2015 Nov 30.

PMID:
26698537
8.

Novel 5-HT6 receptor antagonists/D2 receptor partial agonists targeting behavioral and psychological symptoms of dementia.

Kołaczkowski M, Marcinkowska M, Bucki A, Śniecikowska J, Pawłowski M, Kazek G, Siwek A, Jastrzębska-Więsek M, Partyka A, Wasik A, Wesołowska A, Mierzejewski P, Bienkowski P.

Eur J Med Chem. 2015 Mar 6;92:221-35. doi: 10.1016/j.ejmech.2014.12.045. Epub 2014 Dec 24.

PMID:
25557493
9.

Cyclic benzamides as mixed dopamine D2/serotonin 5-HT2 receptor antagonists: potential atypical antipsychotic agents.

Norman MH, Rigdon GC, Navas F 3rd, Cooper BR.

J Med Chem. 1994 Aug 5;37(16):2552-63.

PMID:
7914539
10.

New 1-aryl-3-(4-arylpiperazin-1-yl)propane derivatives, with dual action at 5-HT1A serotonin receptors and serotonin transporter, as a new class of antidepressants.

Martínez-Esparza J, Oficialdegui AM, Pérez-Silanes S, Heras B, Orús L, Palop JA, Lasheras B, Roca J, Mourelle M, Bosch A, Del Castillo JC, Tordera R, Del Río J, Monge A.

J Med Chem. 2001 Feb 1;44(3):418-28.

PMID:
11462981
11.

The impact of the halogen bonding on D2 and 5-HT1A/5-HT7 receptor activity of azinesulfonamides of 4-[(2-ethyl)piperidinyl-1-yl]phenylpiperazines with antipsychotic and antidepressant properties.

Partyka A, Kurczab R, Canale V, Satała G, Marciniec K, Pasierb A, Jastrzębska-Więsek M, Pawłowski M, Wesołowska A, Bojarski AJ, Zajdel P.

Bioorg Med Chem. 2017 Jul 15;25(14):3638-3648. doi: 10.1016/j.bmc.2017.04.046. Epub 2017 May 4.

PMID:
28529043
12.

Novel 3-(1,2,3,6-Tetrahydropyridin-4-yl)-1H-indole-Based Multifunctional Ligands with Antipsychotic-Like, Mood-Modulating, and Procognitive Activity.

Bucki A, Marcinkowska M, Śniecikowska J, Więckowski K, Pawłowski M, Głuch-Lutwin M, Gryboś A, Siwek A, Pytka K, Jastrzębska-Więsek M, Partyka A, Wesołowska A, Mierzejewski P, Kołaczkowski M.

J Med Chem. 2017 Sep 14;60(17):7483-7501. doi: 10.1021/acs.jmedchem.7b00839. Epub 2017 Aug 18.

PMID:
28763213
13.

New antipsychotic agents with serotonin and dopamine antagonist properties based on a pyrrolo[2,1-b][1,3]benzothiazepine structure.

Campiani G, Nacci V, Bechelli S, Ciani SM, Garofalo A, Fiorini I, Wikström H, de Boer P, Liao Y, Tepper PG, Cagnotto A, Mennini T.

J Med Chem. 1998 Sep 24;41(20):3763-72.

PMID:
9748351
14.

PD 158771, a potential antipsychotic agent with D2/D3 partial agonist and 5-HT(1A) agonist actions. II. Preclinical behavioral effects.

Corbin AE, Meltzer LT, Ninteman FW, Wiley JN, Christoffersen CL, Wustrow DJ, Wise LD, Pugsley TA, Heffner TG.

Neuropharmacology. 2000 Apr 27;39(7):1211-21.

PMID:
10760363
15.

New pyridobenzodiazepine derivatives: modifications of the basic side chain differentially modulate binding to dopamine (D(4.2), D(2L)) and serotonin (5-HT(2A)) receptors.

Liégeois JF, Eyrolles L, Ellenbroek BA, Lejeune C, Carato P, Bruhwyler J, Géczy J, Damas J, Delarge J.

J Med Chem. 2002 Nov 7;45(23):5136-49.

PMID:
12408724
16.
17.

Novel 5-HT7R antagonists, arylsulfonamide derivatives of (aryloxy)propyl piperidines: Add-on effect to the antidepressant activity of SSRI and DRI, and pro-cognitive profile.

Canale V, Partyka A, Kurczab R, Krawczyk M, Kos T, Satała G, Kubica B, Jastrzębska-Więsek M, Wesołowska A, Bojarski AJ, Popik P, Zajdel P.

Bioorg Med Chem. 2017 May 15;25(10):2789-2799. doi: 10.1016/j.bmc.2017.03.057. Epub 2017 Mar 29.

PMID:
28391970
18.

5-HT reuptake inhibitors with 5-HT(1B/1D) antagonistic activity: a new approach toward efficient antidepressants.

Matzen L, van Amsterdam C, Rautenberg W, Greiner HE, Harting J, Seyfried CA, Böttcher H.

J Med Chem. 2000 Mar 23;43(6):1149-57.

PMID:
10737747
19.

Conformationally constrained butyrophenones with affinity for dopamine (D(1), D(2), D(4)) and serotonin (5-HT(2A), 5-HT(2B), 5-HT(2C)) receptors: synthesis of aminomethylbenzo[b]furanones and their evaluation as antipsychotics.

Raviña E, Casariego I, Masaguer CF, Fontenla JA, Montenegro GY, Rivas ME, Loza MI, Enguix MJ, Villazon M, Cadavid MI, Demontis GC.

J Med Chem. 2000 Nov 30;43(24):4678-93.

PMID:
11101359

Supplemental Content

Support Center